Primary contact

The MediBeacon system uses an optical skin sensor combined with a proprietary biocompatible optical diagnostic agent that glows in the presence of light. The goal is to provide clinicians with continuous physiological monitoring, with plans to expand the offering to surgical guidance, and imaging of pathological disease in the human population. The company's first product platform, Transdermal GFR Monitor, is focused on real-time and cost-effective monitoring of kidney function. MediBeacon has completed clinical studies in healthy and impaired subjects. It holds numerous patents on its light-activated agents.
Primary contact

Funding 💰

Total $45.6M
Select investors HC2 Holdings, BioGenerator, Jump Capital, Missouri Technology Corporation
Last update: April 13, 2018